An open-label pilot trial of minocycline in children as a treatment for Angelman syndrome

BMC Neurology

Table 3 Patient populations & clinical measures

Participant	Sex	Age (Months)	Daily dosage (mg)	CGI			EEG
Participant	Sex	Age (Months)	Daily dosage (mg)	T1	T2	T3	T1	T2	T3
1	Female	100	200	5	4	5	4	7	4
2	Male	88	100	4	4	4	8	9	6
3	Female	124	200	7	6	7	11	7	12
4	Female	128	200	6	5	5	14	12	11
5	Male	119	100	4	4	3	5	5	3
6	Male	160	200	5	4	5	6	6	6
7	Female	89	100	5	5	5	5	9	5
8	Female	101	200	5	5	5	8	5	9
9	Male	60	100	6	5	6	15	9	12
10	Male	86	200	4	4	4	8	8	6
11	Female	89	100	5	5	5	12	9	8
12	Female	112	200	4	3	3	9	8	5
13	Female	111	100	6	4	4	9	9	6
14	Male	76	200	6	6	6	9	9	8
15	Male	127	200	6	5	6	6	6	4
16	Male	63	100	7	6	6	14	11	16
17	Female	72	100	5	4	5	14	12	12
18	Female	83	100	5	4	3	9	9	9
19	Male	97	100	5	4	4	5	7	11
20	Male	125	200	5	5	5	10	15	3
21	Male	130	200	7	7	7	10	9	10
22	Male	148	200	8	7	7	4	3	8
23	Male	120	200	5	5	5	14	13	13
24	Male	87	100	7	7	-	7	9	-
25	Female	85	100	7	6	7	13	13	9
	Mean ± Standard Deviation			5.56 ± 1.12	*4.96 ± 1.10	*5.08 ± 1.25	9.16 ± 3.47	8.76 ± 2.80	8.16 ± 3.47
	Standard Error of the Mean			0.224	0.220	0.255	0.694	0.561	0.709
	η ²				0.05			0.05

η² (Partial Eta squared) is a measure of effect size. 0.01 suggests a small effect, 0.06 a medium effect and 0.14 a large effect.
*Indicates p < 0.05 when the time point is compared to T1 (baseline).

ISSN: 1471-2377